Medication for Generalized Anxiety Disorder: Options, Benefits, and Risks
Updated: Oct 8
Author: Ukrainian Psychological Hub · Published: September 30, 2026 · Editorial Policy
Medication can reduce the persistent worry, tension, sleep disruption, irritability, and other symptoms of generalized anxiety disorder (GAD), but there is no single medication that is best for everyone. For adults, selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) have the strongest contemporary evidence and are commonly used as first-line pharmacologic options. Other choices can include buspirone and, depending on the country and clinical context, pregabalin. Benzodiazepines can reduce anxiety quickly but carry important risks of tolerance, physical dependence, withdrawal, misuse, and sedation.
A 2025 Cochrane review of 37 randomized trials involving 12,226 adults found high-certainty evidence that antidepressants improved treatment response compared with placebo. At the same time, medication decisions require a tradeoff between expected benefit, adverse effects, withdrawal risk, other health conditions, drug interactions, pregnancy considerations, age, prior treatment response, and patient preference.
This article is specifically about medication for GAD. It does not treat every experience of anxiety as a disorder, turn a screening score into a diagnosis, or assume that medication evidence for GAD applies unchanged to panic disorder, social anxiety disorder, specific phobia, OCD, PTSD, or other neighboring conditions. For the broader diagnostic family, see Anxiety Disorders: Symptoms, Types, Diagnosis, and Treatment.
Educational information cannot determine which prescription, dose, combination, or taper is appropriate for an individual. Starting, switching, combining, or stopping psychiatric medication should be planned with a qualified prescriber who can review the full medical and medication context.
What Medications Are Used for Generalized Anxiety Disorder?
The main medication groups used for GAD are SSRIs, SNRIs, buspirone, pregabalin in jurisdictions where it is approved or otherwise clinically used, and selected short-term or second-line agents. The National Institute of Mental Health identifies SSRIs, SNRIs, benzodiazepines, and buspirone among medications that may be used for GAD, while emphasizing that treatment choice depends on the person's needs, preferences, and medical situation.
The NICE guideline for adult GAD recommends an SSRI when drug treatment is chosen and suggests another SSRI or an SNRI if the first SSRI is ineffective. If SSRIs and SNRIs cannot be tolerated, NICE says pregabalin may be considered. It advises against routine benzodiazepine treatment for GAD except as a short-term measure during crises and advises against antipsychotic treatment for GAD in primary care.
These recommendations are not a universal formulary. Regulatory approvals differ by country, insurance coverage differs, and a drug can have evidence for GAD without being formally approved for GAD in a particular jurisdiction. Conversely, regulatory approval does not mean a medication is the best option for every patient.
How Strong Is the Evidence That Medication Helps GAD?
The clearest recent synthesis for antidepressants is the 2025 Cochrane review. Across 37 randomized controlled trials, antidepressants produced a treatment-response risk ratio of 1.41 compared with placebo. The estimated number needed to treat for one additional beneficial response was 7. Overall dropout rates were similar between antidepressants and placebo, but dropout because of adverse effects was more common with antidepressants.
That evidence is clinically meaningful, but its boundaries matter. The trials lasted four to 28 weeks and primarily enrolled adults with moderate-to-severe GAD without serious medical comorbidities. The evidence therefore supports an average short- to medium-term benefit in studied populations; it does not predict exactly how any one person will respond.
A large 2019 Lancet network meta-analysis of 89 trials and 25,441 participants found several effective pharmacologic options. Duloxetine, pregabalin, venlafaxine, and escitalopram showed efficacy compared with placebo with relatively good acceptability in that analysis. Other drugs also showed benefit, but some estimates were based on smaller samples. Quetiapine produced a large symptom effect in the network analysis but was poorly tolerated; paroxetine and benzodiazepines were effective but less well tolerated than placebo.
Network meta-analysis can compare many treatments using both direct and indirect evidence, but it does not create a personalized ranking. Differences in trial populations, dosing protocols, duration, outcome measures, and adverse-effect reporting limit any simple claim that one drug is universally superior.
SSRIs for GAD
Selective serotonin reuptake inhibitors are antidepressants that alter serotonin signaling. Their name can be confusing in an anxiety context: a medication can be classified as an antidepressant and still have demonstrated efficacy for an anxiety disorder.
Examples with U.S. GAD indications include escitalopram and paroxetine in adults. The current Lexapro (escitalopram) label includes GAD in adults and pediatric patients age 7 years and older. The current Paxil (paroxetine) label includes GAD in adults but states that paroxetine is not approved for pediatric patients.
Other SSRIs may be used for GAD depending on the country, guideline, clinician, and patient. NICE, for example, specifically considers sertraline when an SSRI is chosen for adult GAD, while noting licensing considerations in its jurisdiction. This illustrates why 'approved medication' and 'guideline-supported medication' are related but not identical concepts.
Benefits of SSRIs
SSRIs can reduce the severity and frequency of generalized worry and associated anxiety symptoms. They can be especially useful when GAD co-occurs with depression or when a long-term daily treatment is preferred over a rapidly acting sedative.
Their benefit is usually gradual. A person may notice some change before full benefit is clear, but it often takes several weeks to judge response. Early improvement, lack of early improvement, and temporary side effects should all be interpreted in the context of the medication, dose, adherence, and time on treatment rather than as a simple success-or-failure verdict.
Common limitations and adverse effects
SSRI adverse effects vary by drug and person. The escitalopram label lists common effects including nausea, insomnia, fatigue or sleepiness, increased sweating, and sexual dysfunction. SSRIs can also cause discontinuation symptoms when stopped abruptly or reduced too quickly.
SSRIs and other antidepressants carry a boxed warning in the United States about increased risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. This warning calls for monitoring; it is not evidence that everyone taking an antidepressant becomes suicidal. New or worsening suicidal thoughts, severe agitation, or major behavioral changes require prompt clinical attention.
SSRIs can also contribute to serotonin syndrome, hyponatremia, bleeding risk in some medication combinations, and activation of mania or hypomania in people with bipolar vulnerability. Prescribers therefore consider other medications, medical history, and possible bipolar disorder before and during treatment.
SNRIs for GAD
Serotonin-norepinephrine reuptake inhibitors affect both serotonin and norepinephrine signaling. Venlafaxine extended release and duloxetine have substantial GAD evidence and U.S. indications.
The Effexor XR (venlafaxine extended-release) label indicates the medication for GAD in adults and describes efficacy established in short-term and six-month placebo-controlled trials. The Cymbalta (duloxetine) label includes GAD in adults and in pediatric patients age 7 years and older.
Benefits of SNRIs
Like SSRIs, SNRIs can reduce generalized anxiety symptoms without the dependence profile of benzodiazepines. They may also be clinically relevant when another approved indication, such as depression or certain pain conditions, is present, although treatment selection still needs to be based on the whole clinical picture.
Risks and tolerability
SNRIs share several antidepressant-class risks with SSRIs, including nausea, sleep changes, sexual adverse effects, serotonin syndrome, discontinuation symptoms, and the boxed warning concerning suicidal thoughts and behaviors in younger patients. Individual SNRIs also have distinct considerations.
Venlafaxine can increase blood pressure in some patients and has a well-recognized discontinuation syndrome. NICE specifically flags withdrawal propensity when choosing among drugs, especially for venlafaxine and paroxetine. The NICE recommendations therefore treat withdrawal profile, side effects, drug interactions, toxicity in overdose, prior experience, and patient preference as part of medication selection rather than as afterthoughts.
Duloxetine has its own hepatic, blood pressure, discontinuation, and interaction considerations. These differences are one reason a class label such as 'SNRI' is not enough to select a specific prescription.
Buspirone for GAD
Buspirone is a nonbenzodiazepine anxiolytic. It is not a sedative in the same way benzodiazepines are, and it does not have the same dependence and withdrawal profile. It is generally taken on a regular schedule rather than used as an immediate rescue medication.
The current DailyMed buspirone label states that buspirone is indicated for management of anxiety disorders or short-term relief of anxiety symptoms and that controlled trials demonstrated efficacy in outpatients whose diagnoses roughly corresponded to GAD. Those original studies used older diagnostic criteria, which is an important historical limitation.
NIMH notes that buspirone can be helpful for GAD and may require about three to four weeks for full effect. Its slower onset means it should not be confused with a rapidly acting benzodiazepine. Evidence summarized in the 2019 network meta-analysis also supported efficacy, although the buspirone evidence base was smaller than for several leading antidepressants.
Possible adverse effects include dizziness, nausea, headache, nervousness, or lightheadedness. Buspirone can also interact with other serotonergic drugs and with medications that affect its metabolism. Its different mechanism and risk profile can make it useful in some treatment plans, but it is not automatically preferable to an SSRI or SNRI.
Pregabalin for GAD
Pregabalin is a gabapentinoid that reduces excitatory neurotransmitter release through binding to the alpha-2-delta subunit of voltage-gated calcium channels. Its regulatory status for GAD is notably different across regions.
In the European Union, EMA lists Lyrica (pregabalin) as indicated for GAD in adults. In the United States, the current Lyrica label lists neuropathic pain, partial-onset seizures, fibromyalgia, and spinal-cord-injury pain, but not GAD. Thus, describing pregabalin simply as 'approved for GAD' without naming the jurisdiction is inaccurate.
The NICE adult GAD guideline says pregabalin can be considered when SSRIs or SNRIs cannot be tolerated. The 2019 network meta-analysis also found pregabalin more effective than placebo with relatively good acceptability. However, pregabalin can cause dizziness and sleepiness, requires attention to renal function, and has misuse and dependence concerns in some patients.
Pregabalin is therefore a genuine evidence-based option in some settings, but its place in treatment depends heavily on jurisdiction, prior response, tolerability, medical comorbidity, substance-use history, and regulatory rules.
Benzodiazepines: Fast Relief, Important Tradeoffs
Benzodiazepines can reduce acute anxiety rapidly by enhancing GABA-mediated inhibition. That speed is their main advantage and also a reason they can feel dramatically different from SSRIs, SNRIs, or buspirone.
For ongoing GAD management, however, major guidance is cautious. NICE advises against benzodiazepines for GAD except as a short-term measure during crises. NIMH likewise notes that clinicians may use them for brief periods because tolerance and dependence can develop.
The FDA boxed-warning communication highlights risks of abuse, misuse, addiction, physical dependence, and withdrawal reactions for the entire benzodiazepine class. Physical dependence can develop even when a medication is taken as prescribed, and abrupt discontinuation or overly rapid dose reduction can trigger severe withdrawal, including seizures.
Sedation, slowed reaction time, impaired coordination, memory problems, falls, and traffic or occupational risks also matter. Combining benzodiazepines with opioids, alcohol, or other central nervous system depressants can be particularly dangerous because of additive sedation and respiratory depression.
Dependence and addiction are different concepts. Physical dependence means the body adapts to continued exposure and withdrawal can occur when the drug is reduced or stopped. Addiction involves compulsive use despite harm. A person can become physically dependent while taking a benzodiazepine exactly as prescribed.
Because GAD is often persistent, a medication strategy built around repeated rapid relief can create long-term tradeoffs. Benzodiazepines can still have legitimate clinical uses, but their benefit-risk profile is different from maintenance treatments designed for regular long-term use.
Hydroxyzine and Other Short-Term Options
Hydroxyzine is a sedating antihistamine with anxiolytic effects. It can reduce anxiety symptoms more quickly than a typical antidepressant, but the GAD evidence base is older and smaller.
A Cochrane review of hydroxyzine for GAD found some evidence of benefit over placebo but concluded that the small number of studies, small sample size, and high risk of bias did not support hydroxyzine as a reliable first-line treatment. The current DailyMed hydroxyzine label also states that effectiveness as an antianxiety agent for long-term use beyond four months has not been systematically assessed.
Drowsiness and anticholinergic effects can be limiting, and hydroxyzine can be problematic in people with certain cardiac rhythm risks or when combined with other sedating medications. Its role is therefore different from an SSRI or SNRI intended as a maintenance treatment.
Other agents sometimes discussed online include tricyclic antidepressants, mirtazapine, agomelatine, gabapentin, beta blockers, and atypical antipsychotics. Evidence, regulatory approval, safety, and clinical role vary substantially. A mention in a trial or a network meta-analysis does not make a drug a routine first-line treatment.
For example, the 2019 network meta-analysis found a large symptom effect for quetiapine but poor tolerability. NICE advises against offering antipsychotics for GAD in primary care. Beta blockers may reduce peripheral adrenergic symptoms in specific situations but are not established core treatments for the diffuse, persistent worry pattern of GAD.
Which GAD Medications Are FDA-Approved in the United States?
U.S. labeling is one useful reference point, but it should not be confused with a complete list of evidence-based choices worldwide. Current U.S. labels include GAD indications for escitalopram in adults and children age 7 and older, duloxetine in adults and children age 7 and older, venlafaxine extended release in adults, and paroxetine in adults.
These indications can be verified in current DailyMed prescribing information for escitalopram, duloxetine, venlafaxine extended release, and paroxetine. Other medications may be used off-label when evidence, guidelines, prior response, and individual clinical circumstances support that choice.
Off-label prescribing is a regulatory concept, not a synonym for experimental or inappropriate treatment. It means the specific indication, age group, formulation, or use is not included in that product's approved label. The quality of evidence and the clinical rationale still need to be evaluated separately.
How Long Does GAD Medication Take to Work?
Onset depends on the medication. Benzodiazepines and hydroxyzine can produce noticeable effects quickly, sometimes within hours. Pregabalin can also act more quickly than standard antidepressants in some trials. SSRIs, SNRIs, and buspirone generally require repeated daily use, and meaningful benefit often develops over weeks.
NIMH notes that SSRIs and SNRIs may take several weeks to start working and that buspirone may need three to four weeks for full effect. NICE recommends explaining the gradual development of anxiolytic benefit and the possibility of early activation symptoms such as increased anxiety, agitation, or sleep difficulty with SSRIs and SNRIs.
A medication that has not produced immediate relief is therefore not necessarily ineffective. Conversely, an immediate sedative effect is not the same as long-term control of GAD. Clinicians distinguish early sensations from sustained change in worry, physical tension, sleep, functioning, and overall symptom burden.
What Counts as a Good Response?
Clinical trials often define response as a substantial reduction on a rating scale, but real-world success involves more than a number. A useful treatment should improve daily functioning as well as symptom severity and should do so with adverse effects that are acceptable to the person taking it.
Examples of meaningful changes include spending less time trapped in uncontrollable worry, sleeping more consistently, being able to concentrate on work or school, reducing reassurance seeking, becoming less physically tense, and returning to activities that anxiety had disrupted.
A questionnaire such as the GAD-7 can track symptom severity, but a score does not diagnose GAD and should not be the only measure of whether medication is working. Diagnosis and follow-up require clinical context, functional impact, other disorders, medical conditions, and medication effects.
Side Effects, Withdrawal, Dependence, and Addiction Are Different
Medication safety discussions become clearer when four concepts are kept separate.
Side effects
Side effects are unwanted effects that occur while taking a medication, such as nausea, dizziness, sexual dysfunction, sleepiness, insomnia, sweating, dry mouth, or gastrointestinal symptoms. Their likelihood and severity depend on the specific drug, dose, individual susceptibility, and interacting medications.
Discontinuation or withdrawal symptoms
Discontinuation symptoms occur when the body has adapted to a medication and exposure falls. SSRIs and SNRIs can cause discontinuation syndromes, especially after abrupt cessation or rapid tapering. Symptoms can include dizziness, sensory disturbances, anxiety, irritability, sleep disruption, flu-like feelings, or gastrointestinal symptoms.
These symptoms do not by themselves imply addiction. They are a physiologic consequence of adaptation. Some antidepressants have more prominent discontinuation profiles than others, which is why taper planning matters.
Physical dependence
Physical dependence is especially important with benzodiazepines and can also be relevant to pregabalin. The FDA benzodiazepine warning emphasizes that dependence may develop with prescribed use and that sudden discontinuation can be dangerous.
Addiction
Addiction is a pattern of compulsive use despite harmful consequences. It overlaps with but is not identical to tolerance or physical dependence. Conflating these concepts can either minimize real risks or unnecessarily stigmatize people who develop expected physiologic dependence during appropriate treatment.
Can GAD Medication Make Anxiety Worse at First?
Yes, some people experience temporary activation after starting or increasing an SSRI or SNRI. This can include increased anxiety, restlessness, agitation, or sleep disturbance. NICE specifically recommends warning patients about this possibility.
New symptoms still need context. Severe agitation, marked behavioral change, emerging suicidal thoughts, symptoms suggestive of mania or hypomania, or a possible severe drug reaction are not simply routine 'startup anxiety' and warrant prompt clinical review.
A person who feels worse after starting medication should not automatically stop it abruptly without guidance, especially if the drug has withdrawal potential. The safer response is to contact the prescriber and describe the timing, severity, accompanying symptoms, dose changes, and other substances or medications involved.
What If the First Medication Does Not Work?
Failure of one medication does not mean medication as a whole cannot help. Lack of benefit may reflect the particular drug, inadequate duration, tolerability-limited dosing, inconsistent adherence, a competing diagnosis, substance or medication effects, or a medical condition that is contributing to symptoms.
NICE recommends considering another SSRI or an SNRI if an initial SSRI is ineffective, while weighing withdrawal profile, side effects, interactions, overdose toxicity, previous treatment experience, and patient preference. The Lancet network meta-analysis likewise concluded that failure of initial pharmacologic therapy is not in itself a reason to abandon pharmacologic treatment.
Before switching or adding medication, clinicians may also revisit the diagnosis. Persistent anxiety can occur with depression, OCD, PTSD, panic disorder, bipolar disorder, ADHD, substance use, medication effects, endocrine conditions, cardiac or respiratory illness, sleep disorders, and other medical problems.
For that broader process, see Anxiety Differential Diagnosis: What Can Look Like an Anxiety Disorder? and Anxiety Symptoms and Medical Differential Diagnosis.
Medication Versus CBT for GAD
Medication and cognitive behavioral therapy are both evidence-based approaches to GAD, but they work through different mechanisms and create different practical tradeoffs. Medication can reduce symptom burden without requiring the time and active practice demanded by psychotherapy. CBT can teach skills for changing worry processes, threat interpretation, avoidance, reassurance seeking, and other maintaining patterns without ongoing pharmacologic exposure.
Neither option is inherently more serious, more legitimate, or more appropriate for every person. Some people prefer psychotherapy, some prefer medication, and some benefit from both. Access, severity, previous response, comorbidity, adverse-effect concerns, pregnancy plans, cost, and personal preference all influence the choice.
This medication page does not own the full GAD-treatment intent. The broader treatment architecture belongs to the separate Generalized Anxiety Disorder Treatment article, and CBT-specific mechanisms and protocols belong to the dedicated CBT article when those canonicals are live. The dedicated CBT page is now live: CBT for Generalized Anxiety Disorder: How It Works and What Evidence Shows. For the broader treatment pathway, see Generalized Anxiety Disorder Treatment: CBT, Medication, and Self-Help.
How Long Should Medication Continue After Improvement?
Stopping as soon as symptoms improve can increase relapse risk for some people. Maintenance decisions therefore consider how severe and persistent GAD has been, how complete the response is, previous relapses, comorbid conditions, adverse effects, and the person's preferences.
NICE recommends continuing effective medication after remission because relapse is common and emphasizes planned review rather than abrupt discontinuation. U.S. product labels for several GAD medications also include maintenance data, including venlafaxine extended release and paroxetine.
There is no single stopping date that applies to everyone. A person who has had repeated episodes, residual symptoms, or major functional impairment may have a different maintenance plan from someone with a first episode that has fully remitted.
When discontinuation is appropriate, the taper is individualized. Drug half-life, dose, duration of use, previous withdrawal symptoms, and patient preference can all matter. Antidepressants and benzodiazepines should not be treated as interchangeable in taper planning because their withdrawal risks differ.
Medication for GAD in Children and Adolescents
Pediatric GAD requires age-specific evidence and monitoring. Adult medication evidence should not simply be copied into children.
Current U.S. labels include GAD indications for escitalopram in patients age 7 and older and duloxetine in patients age 7 and older. Venlafaxine extended release and paroxetine are not approved for pediatric GAD in their current U.S. labels.
Antidepressant labels carry a boxed warning about increased suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Monitoring is especially important during early treatment and dose changes. Pediatric treatment also considers growth, development, school functioning, family context, and the strong role of evidence-based psychotherapy.
A child's anxiety symptoms should first be assessed as a clinical pattern rather than inferred from a test score alone. Screening tools can support assessment, but they do not replace a diagnostic evaluation.
Pregnancy, Postpartum, and Breastfeeding
Medication decisions during pregnancy and lactation require a separate benefit-risk analysis. Untreated clinically significant anxiety can itself affect functioning, sleep, nutrition, prenatal care, and quality of life, while medications can have pregnancy- or infant-specific risks.
The American College of Obstetricians and Gynecologists clinical practice guideline reviews psychiatric medication treatment for depression, anxiety, anxiety-related disorders, bipolar disorder, and acute psychosis during pregnancy and postpartum. The central clinical task is individualized assessment rather than an automatic rule to continue or discontinue every medication.
Pregnancy is also a poor setting for abrupt self-directed discontinuation. Stopping an antidepressant suddenly can produce withdrawal symptoms or symptom recurrence; abrupt benzodiazepine withdrawal can be medically dangerous. People who are pregnant, planning pregnancy, or breastfeeding should review the specific drug, timing, alternatives, and monitoring plan with their prescriber and obstetric clinician.
Older Adults and Medical Comorbidity
Age and medical conditions can change medication risk even when the psychiatric diagnosis is the same. Older adults may be more vulnerable to sedation, falls, cognitive effects, hyponatremia, blood pressure changes, and drug-drug interactions. Kidney or liver impairment can alter exposure to some medications.
A long medication list also increases the chance of interactions. Serotonergic combinations can increase serotonin-syndrome risk; anticoagulants or antiplatelet drugs can interact with some antidepressants to increase bleeding risk; central nervous system depressants can amplify sedation and respiratory risk.
This is why online lists of 'best anxiety medications' are incomplete by design: they usually cannot incorporate renal function, liver function, cardiac history, pregnancy, seizure risk, bipolar history, substance use, current prescriptions, supplements, or previous adverse reactions.
When Symptoms May Be Caused by Medication or Another Medical Condition
Not every new episode of anxiety in someone taking medication is GAD. Stimulants, decongestants, corticosteroids, thyroid medication, caffeine, some bronchodilators, recreational substances, withdrawal states, and many other exposures can produce or intensify anxiety-like symptoms.
A clinician may need to consider substance- or medication-induced anxiety disorder when the timing and pharmacology support that explanation. Cardiac, respiratory, endocrine, neurologic, sleep-related, and other medical conditions can also produce symptoms that overlap with anxiety.
Palpitations, chest pain, shortness of breath, fainting, severe dizziness, new neurologic symptoms, or other concerning physical symptoms should not be assigned to anxiety simply because the person also feels anxious. Medical urgency depends on the symptom pattern and context, not on whether anxiety is present.
How Clinicians Choose Among GAD Medications
A high-quality medication decision is a matching problem, not a popularity contest. Prescribers commonly consider the strength of GAD-specific evidence, regulatory indication, previous response, co-occurring depression or other disorders, side-effect priorities, withdrawal profile, interaction burden, medical conditions, pregnancy or lactation, age, substance-use history, cost, availability, and patient preference.
For one person, avoiding sedation may be crucial because of driving or safety-sensitive work. For another, sexual adverse effects may determine adherence. Someone with a history of severe antidepressant discontinuation symptoms may value a drug with a more forgiving pharmacokinetic profile. Someone with kidney disease may need a different strategy from someone with significant liver disease.
Shared decision-making also includes a plan for what happens next: which symptoms and functional outcomes will be tracked, when follow-up will occur, what adverse effects should trigger contact, how long an adequate trial is expected to take, and what the alternatives are if benefit is insufficient.
How Medication Response Should Be Monitored
Monitoring should distinguish symptom change, functional change, and adverse effects. Asking only 'Are you less anxious?' misses important information.
Useful follow-up questions include whether worry is easier to disengage from; whether sleep, concentration, irritability, and muscle tension are changing; whether work, school, relationships, or daily tasks are improving; whether avoidance or reassurance seeking has changed; and whether side effects are interfering with functioning.
Structured measures such as the GAD-7 can make symptom trends easier to see, but they remain measurement tools. For the broader distinction, see Anxiety Screening vs Diagnosis: Why a Questionnaire Is Not a Clinical Diagnosis.
When to Seek Prompt or Urgent Medical Help
Prompt clinical contact is appropriate for severe or rapidly worsening adverse effects, new suicidal thoughts, marked agitation, symptoms suggestive of mania or hypomania, severe confusion, suspected serotonin syndrome, a serious allergic reaction, or significant withdrawal symptoms.
Emergency care may be necessary for seizures, loss of consciousness, severe breathing difficulty, suspected overdose, severe chest pain, or other potentially life-threatening symptoms. These situations cannot be safely distinguished from ordinary anxiety through an online article.
If a concerning symptom appears after a medication change, the timing is useful information but does not prove the medication is the cause. Clinicians may need to evaluate the drug, other substances, medical conditions, and the underlying disorder together.
Frequently Asked Questions
What is the first-line medication for generalized anxiety disorder?
SSRIs and SNRIs are the most commonly supported first-line medication classes for adult GAD. A specific first choice depends on the guideline, country, prior response, side effects, interactions, comorbidity, and patient preference. NICE recommends an SSRI when drug treatment is chosen and then another SSRI or an SNRI if the first option is ineffective.
What is the best medication for GAD?
There is no universally best medication. Contemporary evidence supports several options, but average trial results do not predict individual tolerability or response. The best-fitting choice is the one with a favorable balance of evidence, safety, tolerability, medical fit, and patient preference for that individual.
Which GAD medications work the fastest?
Benzodiazepines and hydroxyzine can produce noticeable effects quickly, while SSRIs, SNRIs, and buspirone generally take longer. Fast relief does not automatically mean better long-term treatment. Benzodiazepines have important dependence and withdrawal risks.
Are SSRIs addictive?
SSRIs are not considered addictive in the same way as substances that produce compulsive reward-seeking, but they can cause physiologic adaptation and discontinuation symptoms. That distinction is why gradual tapering may be needed even though addiction is not the expected pattern.
Can you become dependent on benzodiazepines even if you take them as prescribed?
Yes. Physical dependence can develop with prescribed benzodiazepine use. The FDA boxed warning emphasizes this risk and warns that abrupt discontinuation or overly rapid dose reduction can cause serious withdrawal reactions, including seizures.
Is pregabalin approved for GAD?
It depends on the jurisdiction. Pregabalin is authorized for adult GAD in the European Union, but the current U.S. Lyrica label does not include GAD as an indication.
Does buspirone work immediately?
No. Buspirone is not a rescue sedative. NIMH notes that it may take three to four weeks to reach full effect.
Can hydroxyzine be used long term for GAD?
Hydroxyzine can reduce anxiety symptoms, but its long-term GAD evidence is limited. Current U.S. labeling notes that effectiveness as an antianxiety agent beyond four months has not been systematically assessed, and an older Cochrane review did not support it as a reliable first-line GAD treatment.
Can medication cure generalized anxiety disorder?
Medication can reduce symptoms and support remission, but 'cure' is not a useful guarantee for a condition that can be chronic or recurrent. Some people remain well after treatment, some experience relapse, and some need longer-term management.
Should I stop medication once I feel better?
Not automatically. Stopping too early can increase relapse risk, and abrupt discontinuation can cause withdrawal with some drugs. Maintenance duration and tapering should be planned with the prescriber.
Can a GAD-7 score tell me which medication I need?
No. GAD-7 is a screening and severity measure, not a prescribing algorithm. Medication choice requires diagnosis, medical history, current medications, risk factors, prior treatment response, and patient preference.
Can medication side effects feel like anxiety?
Yes. Activation, restlessness, insomnia, dizziness, palpitations, tremor, or gastrointestinal symptoms can overlap with anxiety sensations. The timing relative to starting or changing a drug matters, but medical and psychiatric differential diagnosis may still be necessary.
Related Articles
References